secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-135267
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M
---------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.
- Collaboration revenue $39.3M, up $21.4M YoY, driven by Kite Pharma agreement amendments.
- Net loss of $7.2M vs $27.3M in Q1 2023, an improvement of $20.1M.
- R&D expenses $32.3M (down $0.6M YoY); G&A expenses $22.7M (up $7.3M YoY) on higher personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/0001193125-24-135267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/d837604d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer